Picard Medical (PMI) EBITDA (2024 - 2026)

Picard Medical has reported EBITDA for 3 years, with the latest figure at -$7.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 36.61% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$29.1 million (down 17.99% YoY), and the FY2025 full-year result was -$27.1 million, down 28.39% from the prior year.
• EBITDA for Q1 2026 stood at -$7.6 million, down from -$4.3 million in the prior quarter.
• The five-year high for EBITDA was -$4.1 million in Q2 2024, with the low at -$10.5 million in Q3 2025.
• Historically, EBITDA has averaged -$6.7 million across 3 years, with a median of -$6.5 million in 2024.
• The largest YoY upside for EBITDA was 51.38% in 2025 against a maximum downside of 68.73% in 2025.
• Picard Medical's EBITDA stood at -$8.8 million in 2024, then surged by 51.38% to -$4.3 million in 2025, then tumbled by 76.99% to -$7.6 million in 2026.
• The last three EBITDA figures came in at -$7.6 million (Q1 2026), -$4.3 million (Q4 2025), and -$10.5 million (Q3 2025), per Business Quant data.